<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="982">
  <stage>Registered</stage>
  <submitdate>17/11/2005</submitdate>
  <approvaldate>17/11/2005</approvaldate>
  <nctid>NCT00256100</nctid>
  <trial_identification>
    <studytitle>Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.</studytitle>
    <scientifictitle>Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2004.066</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fondaparinux Sodium

Active Comparator: One - Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study

Active Comparator: Two - Fondaparinux will be used as the anticoagulant in the sencond arm of the study


Treatment: drugs: Fondaparinux Sodium
The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to the current standard haemofilter anticoagulant, enoxaparin.</outcome>
      <timepoint>Duration of the haemofilter life</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the incidence of complications, primary bleeding with fondaparinux compared to enoxaparin in this setting.</outcome>
      <timepoint>Until hospital discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Adult patients (18 years or over) admitted to the ICU and expected to stay for more
             than 48 hours.

          2. Patients who require continuous renal replacement therapy.

          3. Patients who consent or if the patient is not competent, the next of kin who consent
             to inclusion in the study. .</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients aged less than 18 years of age.

          2. Patients who are pregnant

          3. Patients with a contraindication to anticoagulation for pre existing bleeding
             diathesis

          4. Patients or next of kin who do not consent to study inclusion. -</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Royal Melbourne Hospital Intensive Care Unit Grattan Street - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new
      drug to prevent blood clotting in the continuous dialysis machine used in intensive care
      patients who have kidney failure.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00256100</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John F Cade</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>